Table 1.

Population: all patients and patients according to initial data set or validation set

	All patients		Initial set		Validation set
	Nb	%	Nb	%	Nb	%
Nb patients	12,572		8381		4191
Age median (range)	58 (18–101)		58 (18–101)		58 (18–100)
<  60	7231	58	4857	58	2374	57
61–65	1810	14	1166	14	644	15
>  65	3525	28	2355	28	1170	28
Median tumor size	14		14		14
<  10	4701	38	3136	38	1565	38
11 to 20	5053	41	3368	41	1685	41
>  20	2679	22	1784	22	895	22
No SN removed
1	3268	31	2203	31	1065	31
2	3374	32	2231	31	1143	33
3	2034	19	1382	20	652	19
> 4	1886	18	1271	18	615	18
Tumor type
Ductal	9793	78	6522	78	3271	78
Lobular	1645	13	1110	13	535	13
Mixt	226	2	144	2	82	2
Others	899	7	599	7	300	7
Grade
1	4246	34	2891	35	1355	33
2	5756	46	3800	46	1956	47
3	2448	20	1611	19	837	20
LVI
Negative	8430	78	5661	78	2769	77
Positive	2400	22	1595	22	805	23
Estrogen receptors
negative	1730	14	1146	14	584	14
positive	10,828	86	7227	86	3601	86
Progesterone receptors
negative	3464	29	2281	29	1183	30
positive	8522	71	5701	71	2821	70
Hormonal receptors
negative	1541	12	1020	12	521	12
positive	11,013	88	7349	88	3664	88
Her2 status
negative	11,350	90	7570	90	3780	90
positive	1222	10	811	10	411	10
Tumor sub types
Luminal A	8998	72	6026	72	2972	71
Luminal B Her2-	1178	9	756	9	422	10
HR+ Her2+	766	6	521	6	245	6
HR- Her 2+	450	4	288	3	162	4
Triple Negative	1091	9	732	9	359	9
pN final
pN0(i-)	8253	66	5507	66	2746	66
pN0(i+)	355	3	233	3	122	3
pN1mi	970	8	660	8	310	7
Macro	2994	24	1981	24	1013	24
Clinical size
T0	2764	23	1831	23	933	23
T1	6784	57	4544	57	2246	56
T2	2115	18	1383	17	732	18
> T3	283	2	187	2	96	2